Author:
Claret Laurent,Lu Jian-Feng,Sun Yu-Nien,Bruno René
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference19 articles.
1. Ratain MJ, Humphrey RW, Gordon GB, Fyfe G, Adamson PC, Fleming TR, Stadler WM, Berry DA, Peck CC (2008) Recommended changes to oncology clinical trial design: revolution or evolution? Eur J Cancer 44:8–11
2. Leff R, Andrews M (2008) Predicting success in phase III studies from phase II results: a new paradigm is needed. J Clin Oncol 26:3653–3654 author reply 3654–3655
3. Bruno R, Claret L (2009) On the use of change in tumor size to predict survival in clinical oncology studies: toward a new paradigm to design and evaluate phase II studies. Clin Pharmacol Ther 86:136–138
4. Guidance for industry end-of-phase 2A meetings (2009) United States food and drug administration. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079690.pdf . Accessed Aug 24 2009
5. Claret L, Girard P, O’Shaughnessy J, Hoff P, Van Cutsem E, Blum J, Zuideveld K, Jorga K, Fagerberg J, Bruno R (2006) Model-based predictions of expected anti-tumor response and survival in phase III studies based on phase II data of an investigational agent [abstract]. J Clin Oncol 24:6025
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献